PLASMA CELL MYELOMA REFRACTORY
Clinical trials for PLASMA CELL MYELOMA REFRACTORY explained in plain language.
Never miss a new study
Get alerted when new PLASMA CELL MYELOMA REFRACTORY trials appear
Sign up with your email to follow new studies for PLASMA CELL MYELOMA REFRACTORY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New cocktail of cancer drugs aims to outsmart relapsed myeloma
Disease control Recruiting nowThis umbrella trial tests the drug isatuximab (Sarclisa) combined with several newer agents, with or without dexamethasone, in adults whose multiple myeloma has returned or stopped responding to at least two prior treatments. About 258 participants will be assigned to different s…
Matched conditions: PLASMA CELL MYELOMA REFRACTORY
Phase: PHASE1, PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New shot aims to control Hard-to-Treat bone marrow cancer
Disease control Recruiting nowThis early-stage study tests a new antibody drug (SAR446523) given as a shot under the skin for people with multiple myeloma that has returned or stopped responding to at least three prior treatments. The study has two parts: first, finding the safest and most effective dose, the…
Matched conditions: PLASMA CELL MYELOMA REFRACTORY
Phase: PHASE1 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Wearable device could simplify multiple myeloma treatment
Disease control Recruiting nowThis study tests a new method of giving the drug isatuximab (Sarclisa) under the skin using a wearable device, combined with two other drugs (carfilzomib and dexamethasone), in 64 adults with multiple myeloma that has returned or not responded to prior therapy. The main goal is t…
Matched conditions: PLASMA CELL MYELOMA REFRACTORY
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC